Hims & Hers (HIMS) stock jumped 7% pre-market after CEO Andrew Dudum projected more than 100,000 monthly Wegovy prescriptions. This follows a truce with Novo Nordisk, allowing Hims to offer FDA-approved weight-loss treatments. The company has begun shipping branded Wegovy and Ozempic as part of a strategic shift away from compounded alternatives.